IICT, Lee Pharma collaborate for synthesis of 2-DG
The collaboration between IICT and Lee Pharma is expected to provide alternatives of cheaper therapeutics against Covid-19.
Hyderabad: In yet another affordable treatment option for patients against Covid-19, Hyderabad-based Indian Institute of Chemical Technology (IICT) has entered into a non-exclusive licensing agreement with Lee Pharma for synthesis of 2-Deoxy-D-Glucose (2-DG). The collaboration between IICT and Lee Pharma is expected to provide alternatives of cheaper therapeutics against Covid-19.
Just a few days ago, the Defense Research and Development Organisation (DRDO) in collaboration with Dr Reddy’s Laboratories had launched 2-DG as an adjunct in treatment of moderate to severe Covid-19 patients. In a limited study that involved about 200 patients, the 2-DG drug, which will be available in the form of sachets, was found to help speed-up recovery and reduce oxygen dependence. The DRDO 2-DG drug, which will cost close to Rs 900 per sachet, has been launched by Dr Reddy’s laboratories.
The Lee Pharma is expected to approach the Drug Controller General of India (DCGI) for the approval of its 2-DG formulation. According to reports, Lee Pharma will manufacture and commercialise the 2-DG sachets from their formulation facility located at SEZ, Duvvada, Visakhapatnam in AP.
The Director of CSIR-IICT, Dr S Chandrashekhar, who was quoted by news agencies, said that the agreement with Lee Pharma will help in providing affordable therapeutic options for treatment of Covid-19. Raghumitra Alla, Director, Lee Pharma said, “The collaboration with IICT for 2-DG API is part of our broader strategy for enhancing Covid-19 treatment options.”
